市场调查报告书
商品编码
1533040
到 2030 年亚太地区填充饰面製造市场预测 - 区域分析 - 按产品、模式和最终用户Asia Pacific Fill Finish Manufacturing Market Forecast to 2030 - Regional Analysis - by Product, Modality, and End User |
2022年,亚太地区填充饰面製造市场价值为18.6735亿美元,预计2030年将达到42.0236亿美元;预计2022年至2030年复合年增长率为10.7%。
新兴市场的低商业成本推动亚太填充饰面製造市场
许多亚洲国家正在成为全球各种生物製药製造商有吸引力的外包地点。中国、印度和亚洲其他国家的低製造和营运成本是推动合约製造的关键因素。此外,中国和印度生物製药行业的最新发展表明该市场潜力巨大。不断增长的生物製剂和生物相似药产品线进一步为亚太地区的合约製造商开闢了新的途径。由于营运成本较低,合约製造主要有利于早期药物创新者。为了满足不断增长的需求,许多 CMO 正在扩大其製造能力。例如,2020年1月,药明康德旗下合全药业有限公司在中国开设了一家新的大型寡核苷酸活性药物成分(API)生产工厂。
亚太地区填充饰面製造市场概览
在亚太地区,中国是填充饰面製造的最大市场。市场的成长主要归因于中国填充剂製造流程的技术进步、市场参与者的不断发展、生物製药行业的扩张以及慢性病盛行率的不断上升。中国有超过500家生物製品/生物製药公司。大多数从事研发的机构是由海归或西方/合资公司设立的。儘管估计差异很大,但分析师认为,中国政府每年透过资助计画在生物技术研发上花费超过 6 亿美元。中国国家和地方政府也投资投资IT企业的准创投公司。
市场参与者正在透过有机和无机成长策略扩大业务。例如,药明生物在中国无锡开设药品工厂,于 2022 年 6 月将预充式註射器 (PFS) 产能提高至 1,700 万支/年。
由合约开发製造组织 (CDMO) 药明生物营运的最新 DP 设施被称为 DP5,它拥有先进的隔离器填充线,可提供可靠、连续的填充服务。据该公司称,这为 PFS 提供了多种体积输送选项,包括 1.25 mL、3 mL、1 mL 和 1 mL。
亚太地区填充饰面製造市场收入及 2030 年预测(百万美元)
亚太地区填充饰面製造市场细分
亚太地区填充表面製造市场根据产品、模式、最终用户和国家进行细分。根据产品,亚太地区灌装製造市场分为消耗品和仪器。到2022年,消耗品细分市场将占据更大的市场份额。
就形式而言,亚太地区填充加工製造市场分为重组蛋白、单株抗体、疫苗、细胞疗法和生物疗法、基因疗法等。 2022 年,疫苗领域占据最大的市场。
依最终用户划分,亚太地区填充剂製造市场分为合约製造组织、生物製药公司等。 2022 年,合约製造组织细分市场占据最大的市场份额。
按国家/地区划分,亚太地区填充饰面製造市场分为中国、日本、印度、澳洲、韩国和亚太地区其他地区。 2022 年,中国将主导亚太地区填充涂料製造市场份额。
Becton Dickinson and Co、Gerresheimer AG、IMA Industria Macchine Automatiche SpA、Maquinaria Industrial Dara SL、Nipro Medical Asia Pacific NV、NNE AS、Optima Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Group SpA、Synte Technology GmbticalH 和 West Services Inc 是亚太地区填充饰面製造市场的一些领导者。
The Asia Pacific fill finish manufacturing market was valued at US$ 1,867.35 million in 2022 and is expected to reach US$ 4,202.36 million by 2030; it is estimated to grow at a CAGR of 10.7% from 2022 to 2030.
Low Business Costs in Emerging Markets Boosts Asia Pacific Fill Finish Manufacturing Market
Many Asian countries are emerging as attractive outsourcing locations for various biopharmaceutical manufacturers across the globe. Low manufacturing and operating costs in China, India, and other countries in Asia are the key factors boosting contract manufacturing. Moreover, recent developments in the biopharmaceutical industry in China and India indicate significant potential for the market. The growing pipelines of biologics and biosimilars are further opening new avenues for the contract manufacturers in APAC. Contract manufacturing mostly benefits early-stage drug innovators owing to lower operational costs. To meet the growing demand, many CMOs are expanding their manufacturing capabilities. For instance, in January 2020, STA Pharmaceutical Co., Ltd-a WuXi AppTec company-opened a new large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in China.
Asia Pacific Fill Finish Manufacturing Market Overview
In Asia Pacific, China is the largest market for fill finish manufacturing. The growth of the market is primarily attributed to the rising technological advancements in fill finish manufacturing processes in China, increasing developments by the market players, the biopharmaceutical industry's expansion, and the growing prevalence of chronic diseases. There are more than 500 biological product/biopharmaceutical companies in China. Most of those involved in R&D were established by returnees from abroad or by Western/joint venture companies. Although estimates vary widely, analysts believe that the Chinese government spends more than US$ 600 million annually on biotech R&D through its funding initiatives. China's national and local governments also invest in quasi-venture capital companies that invest in IT enterprises.
The market players are expanding their business through organic and inorganic growth strategies. For instance, WuXi Biologics increased the capacity of prefilled syringes (PFS) to 17 million units yearly in June 2022 by opening its drug product factory in Wuxi, China.
The most recent D.P. facility operated by WuXi Bio, a contract development manufacturing organization (CDMO), is called DP5, and it has an advanced isolator filling line for reliable, continuous filling services. According to the company, this provides PFS with a variety of volume delivery options, including 1.25 mL, 3 mL, 1 mL, and 1 mL.
Asia Pacific Fill Finish Manufacturing Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Fill Finish Manufacturing Market Segmentation
The Asia Pacific fill finish manufacturing market is segmented based on product, modality, end user, and country. Based on product, the Asia Pacific fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held a larger market share in 2022. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.
In terms of modality, the Asia Pacific fill finish manufacturing market is segmented into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held the largest market share in 2022.
By end user, the Asia Pacific fill finish manufacturing market is categorized into contract manufacturing organizations, biopharmaceutical companies, and others. The contract manufacturing organizations segment held the largest market share in 2022.
Based on country, the Asia Pacific fill finish manufacturing market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific fill finish manufacturing market share in 2022.
Becton Dickinson and Co, Gerresheimer AG, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Asia Pacific NV, NNE AS, Optima Packaging Group Gmbh, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc are some of the leading players operating in the Asia Pacific fill finish manufacturing market.